



BRIAN SANDOVAL
Governor

STATE OF NEVADA
DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 E. William Street, Suite 101
Carson City, Nevada 89701
(775) 684-3600

RHICARD WHITLEY
Interim Director

LAURIE SQUARTSOFF
Administrator

NOTICE OF PUBLIC MEETING – DRUG USE REVIEW BOARD

AGENDA

Date of Posting: April 7, 2015

Date of Meeting: Thursday, April 23, 2015 at 5:30 PM

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Drug Use Review Board (DUR).

Place of Meeting: Best Western Plus Airport Plaza Hotel
1981 Terminal Way
Reno, NV 89502
Phone: (775) 348-6370

AGENDA

1. Call to Order and Roll Call
2. Public Comment on Any Matter on the Agenda
3. Administrative
 - a. **For Possible Action:** Review and Approve Meeting Minutes from January 22, 2015.
 - b. Status Update by DHCFP
 - i. Public Comment
 - ii. Medicaid's update of the legislative session
4. Presentation and Discussion of Nevada's Health Care Guidance Program
 - a. Dr. Amy Khan, MD, MPH, Medical Director, Nevada Health Care Guidance Program, McKesson Care Management
5. Clinical Presentations

- a. **For Possible Action:** Discussion on Psychotropics for Children and Adolescents prior authorization process and policy.
 - i. Public comment on the prior authorization process and policy.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by the Board and review of utilization data.
 - iv. Review prior authorization criteria and possible adoption of revised criteria.

- b. **For Possible Action:** Discussion and possible adoption of policy and delivery model for Vivitrol® (naltrexone)
 - i. Public comment on adoption of policy.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by the Board and review of utilization data.
 - iv. Possible adoption of prior authorization criteria/policy.

- c. **For Possible Action:** Discussion and proposed adoption of prior of clinical prior authorization criteria for Ombitasvir/paritaprevir/ritonavir and dasabuvir (Viekira Pak®).
 - i. Public comment on proposed clinical prior authorization criteria.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by the Board and review of utilization data.
 - iv. Proposed adoption of updated prior authorization criteria.

- d. **For Possible Action:** Discussion and proposed adoption of prior authorization criteria for Sodium oxybate (Xyrem®)
 - i. Public Comment on proposed clinical prior authorization criteria.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by the Board and review of utilization data.
 - iv. Proposed adoption of updated prior authorization criteria

- e. **For Possible Action:** Discussion and proposed adoption of updated clinical prior authorization criteria for Omalizumab (Xolair®).
 - i. Public comment on proposed clinical prior authorization criteria.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by Board and review of utilization data.
 - iv. Proposed adoption of updated prior authorization criteria.

- f. **For Possible Action:** Discussion and proposed adoption of prior authorization criteria for Naproxen/esomeprazole magnesium (Vimovo®)
 - i. Public Comment on proposed clinical prior authorization criteria.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by the Board and review of utilization data.
 - iv. Proposed adoption of updated prior authorization criteria.

- g. **For Possible Action:** Discussion and proposed adoption of updated clinical prior authorization criteria for Hydrocodone extended release (Zohydro ER®).
 - i. Public comment on proposed clinical prior authorization criteria.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by Board and review of utilization data.
 - iv. Proposed adoption of updated prior authorization criteria.
- h. **For Possible Action:** Discussion and proposed adoption of updated clinical prior authorization criteria for Prednisone delayed-release (Rayos®).
 - i. Public comment on proposed clinical prior authorization criteria.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by Board and review of utilization data.
 - iv. Proposed adoption of updated prior authorization criteria.

6. Public Comment on any DUR Board Requested Report

7. DUR Board Requested Reports

- a. Report on Top 10 Black Box warning medications:
 - i. Discussion by the Board and review of utilization data.
- b. Report on controlled substance utilization and trends.
 - i. Discussion by the Board and review of utilization data.
- c. Report on psychotropic drug use in children.
 - i. Discussion by the Board and review of utilization data.
- d. Report on fluoxetine utilization in children, duration of treatment
 - i. Discussion by the Board and review of utilization data.
- e. Report on buprenorphine and buprenorphine/naloxone use.
 - i. Discussion by the Board and review of utilization data.
- f. Report on Nevada Medicaid Lock-in Program
 - i. Discussion by the Board and review of utilization data.
- g. Report on diabetic patient compliance for blood glucose monitoring receiving insulin

- i. Discussion by the Board and review of utilization data.
- h. Report on Asthma treatment utilization.
 - i. Discussion by the Board and review of utilization data.
- i. Report on Guaifenesin with Codeine Utilization.
 - i. Discussion by the Board and review of utilization data.

8. Public Comment on any Standard DUR Report

9. Standard DUR Reports

- j. Review of Prescribing/Program Trends.
 - i. Top 10 Therapeutic Classes for Q3 2014, Q4 2014, and Q1 2015 (by Payment and by Claims).
 - ii. Top 50 Drugs of Q3 2014, Q4 2014, and Q1 2015 (by Payment and by Claims).
- k. Concurrent Drug Utilization Review (ProDUR)
 - i. Review of Q3 2014, Q4 2014, and Q1 2015.
 - ii. Review of Top Encounters by Problem Type.
- l. Retrospective Drug Utilization Review (RetroDUR)
 - i. Status of previous quarter.
 - ii. Status of current quarter.
 - iii. Review and discussion of responses.

8. Closing Discussion

- a. Public comments on any subject.
- b. Date and location of the next meeting.
 - i. Discussion of the time of the next meeting.
- c. Adjournment.

Nevada Medicaid is unaware of any financial impact to other entities or local government due to this public hearing, other than as stated above.

PLEASE NOTE: Items may be taken out of order at the discretion of the chairperson.

Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comment may be limited to 5 minutes.

This notice and agenda have been posted at www.dhcfp.nv.gov and <http://notice.nv.gov>

Notice of this meeting and draft copies of the changes will be available on or after the date of this notice at the DHCFP Web site www.dhcfp.nv.gov, Carson City Central office and Las Vegas DHCFP. The agenda posting of this meeting can be viewed at the following locations: Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the meeting materials will be mailed to you. Requests and/or written comments may be sent to Rita Mackie at the Division of Health Care Financing and Policy, 1100 E. William Street, Suite 101, Carson City, NV 89701, at least 3 days before the public hearing.

All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.

Note: We are pleased to make reasonable accommodations for members of the public who are physically challenged and wish to attend the meeting. If special arrangements for the meeting are necessary, please notify the Division of Health Care Financing and Policy, in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Rita Mackie at (775) 684-3681, as soon as possible, or e-mail at rmackie@dhcfp.nv.gov